Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2019

View Archived Issues

Novel transgenerational mouse model of insulin resistance

Mycobiome linked to pancreatic cancer

Dual inhibition of TGF-beta and AXL as novel therapeutic approach in metastatic CRC

rSIFN-co demonstrates antitumor activity in phase I study in advanced solid tumors

Phase I results for DNA vaccine MVI-118 in patients with metastatic prostate cancer

C-75 improves survival of mice with sepsis through blocking TLR/MYD88 signaling in neutrophils

Enrollment underway in phase I/II study of CTNS-RD-04 stem cell gene therapy for cystinosis

First cohort subject dosed in phase I study of SCD inhibitor YTX-7739

NKTR-358 begins new phase Ib studies in psoriasis and atopic dermatitis

Inhaled AZD-8154 demonstrates superior pharmacokinetics over intravenous administration

Hawaii Biotech divulges compounds for anthrax

Biogen patents OGA inhibitors

H. Lee Moffitt Cancer Center and Research Institute presents YAP1/POU5F1 interaction inhibitors

Aerie Pharmaceuticals synthesizes new kinase inhibitors

Genentech patents TRPA1 antagonists

Dermavant initiates phase IIa study of cerdulatinib gel in vitiligo

Phase III extension study of VM-202 in diabetic peripheral neuropathy meets primary endpoint

BARDA contract supports Platelet BioGenesis' development of donor-independent platelets

Advaxis updates median overall survival data from phase I/II study of ADXS-PSA in metastatic CRPC

FDA approves Beovu for wet age-related macular degeneration

Evaluating gepotidacin in the treatment of uncomplicated urinary tract infections: a phase IIa study

Three win Nobel for hypoxia work

Bavarian Nordic begins first-in-human study of MVA-BN-WEV for equine encephalitis virus

ONL Therapeutics advances ONL-1204 into phase I study for retinal detachment